<DOC>
	<DOCNO>NCT01973608</DOCNO>
	<brief_summary>This Phase 2a , open-label , parallel group , partly randomize dose escalation trial ass safety efficacy low dose , intermediate dose , high dose MSB0010445 give intravenous infusion subject advance ( unresectable metastatic ) melanoma combination stereotactic body radiation therapy ( SBRT ) .</brief_summary>
	<brief_title>MSB0010445 Stereotactic Body Radiation Therapy Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Advanced unresectable metastatic melanoma , previously treat ipilimumab ; antimelanoma treatment , include antiPD/PDL1 immunotherapy , allow provide treatment last dose treatment trial enrolment Subjects need one lesion irradiate least 1 measurable lesion outside radiation field , different lesion irradiate one lesion biopsied treatment SBRT MSB0010445 one lesion outside radiation field biopsied treatment MSB0010445 The lesion biopsied Baseline lesion irradiate The lesion biopsied treatment lesion irradiate biopsied Baseline Signed write informed consent Male female subject least 18 year age Life expectancy great equal ( &gt; = ) 4 month Eastern cooperative oncology group ( ECOG ) performance status 0 1 Other protocol define inclusion criterion could apply Active central nervous system metastasis Treatment systemic anticancer therapy within 30 day first dose SBRT Preexisting pericardial effusion history Grade &gt; =2 pleural effusion ascites within 3 month first dose SBRT Concurrent systemic therapy steroid immunosuppressive agent except shortterm systemic steroid allergic reaction Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>MSB0010445</keyword>
	<keyword>Dose limit toxicity</keyword>
	<keyword>Stereotactic body radiation therapy</keyword>
</DOC>